Top Tweets for #ASH20VR

over 4 years ago

Ive been using personal hashtags for many years now. For key myeloma & healthcare cost related tweets check out: #MyelomaVR #CostVR For my picks at @ASH_hematology @ASCO etc check out: #ASH17VR #ASH18VR #ASH19VR #ASCO18VR #ASCO19VR #ASH19VR #ASH20VR #ASCO21VR #ASH21VR

Vincent Rajkumar

@VincentRK

over 4 years ago

Attending #ASH21 ? For those interested: I have been using personal hashtags for a few years now to tag the best of the best myeloma abstracts, along with my comments. For my picks at @ASH_hematology #ASH17VR #ASH18VR #ASH19VR #ASH20VR This year: #ASH21VR

Vincent Rajkumar

@VincentRK

over 5 years ago

For those interested: I have been using personal hashtags for a few years now. For my picks at @ASH_hematology @ASCO etc, search: #ASH17VR #ASH18VR #ASH19VR #ASCO18VR #ASCO19VR #IMW2019VR #ASH19VR #ASH20VR #ASCO20VR For key myeloma and healthcare costs: #MyelomaVR #CostVR

Mike Thompson, MD, PhD, FASCO

@mtmdphd

over 5 years ago

Myeloma / Plasma Cell Dyscrasia ~ #ASH20Top10 #mmsm #mmMRD #ASH20 #ASH20DA #ASH120LC #ASH20BD #ASH20JM #ASH20MT #ASH20NS #ASH20OL #ASH20PH #ASH20RC #ASHRF #ASH20SB #ASH20SK #ASH20SU #ASH20VR - @mtmdphd Table Update: Dec 1, 2020 cc @grpetersen1 #ASCO21

mtmdphd's tweet photo. Myeloma / Plasma Cell Dyscrasia ~ #ASH20Top10 #mmsm #mmMRD #ASH20
#ASH20DA #ASH120LC #ASH20BD #ASH20JM #ASH20MT #ASH20NS #ASH20OL #ASH20PH #ASH20RC #ASHRF #ASH20SB
#ASH20SK #ASH20SU #ASH20VR - @mtmdphd Table Update: Dec 1, 2020 cc @grpetersen1 #ASCO21 https://t.co/prs0qAlq1k

Vincent Rajkumar

@VincentRK

over 5 years ago

I’m so slow at watching all #ASH20 presentations!! So ASH will continue for me for the rest of the week. And I’ll keep posting comments on key presentations. For my absolute top picks in myeloma, search #ASH20VR @MyelomaTeacher @mtmdphd @NorthTxMSG @grpetersen1

Vincent Rajkumar

@VincentRK

almost 6 years ago

#ASH20 IFM 2009 trial results presented by @PerrotAurore On intent to treat basis early and delayed stem cell transplantation led to identical overall survival at 8 years. Timely given the pandemic situation. See thread on what these results mean. #ASH20VR @ASH_hematology

VincentRK's tweet photo. #ASH20 IFM 2009 trial results presented by @PerrotAurore

On intent to treat basis early and delayed stem cell transplantation led to identical overall survival at 8 years. Timely given the pandemic situation. See thread on what these results mean. #ASH20VR @ASH_hematology https://t.co/i0PmcjgUsj

Vincent Rajkumar

@VincentRK

almost 6 years ago

#ASH20 Here is the second of the two new advances I’m most impressed with. Cevostamab (bi-specific targeting FcRH5 and CD3 shows impressive activity in refractory myeloma. Again targets something other than BCMA or CD38. @CohenAd_MMdoc @Rfonsi1 @PennCancer @genentech #ASH20VR

$VincentRK's tweet photo. #ASH20 Here is the second of the two new advances I’m most impressed with. Cevostamab (bi-specific targeting FcRH5 and CD3 shows impressive activity in refractory myeloma. Again targets something other than BCMA or CD38. @CohenAd_MMdoc @Rfonsi1 @PennCancer @genentech #ASH20VR https://t.co/IM8uA08ooY$

Vincent Rajkumar

@VincentRK

almost 6 years ago

#ASH20 There are 2 new advances in myeloma that I am most impressed with. This is one: Talquetamab (bi specific antibody targeting GPRC5D & CD3) shows impressive activity in refractory myeloma. It targets something other than BCMA or CD38. #ASH20VR #AjayChari @JanssenUS

$VincentRK's tweet photo. #ASH20 There are 2 new advances in myeloma that I am most impressed with. This is one: Talquetamab (bi specific antibody targeting GPRC5D & CD3) shows impressive activity in refractory myeloma. It targets something other than BCMA or CD38. #ASH20VR #AjayChari @JanssenUS https://t.co/6g7JIWdXUz$

Vincent Rajkumar

@VincentRK

almost 6 years ago

#ASH20 My colleague @myelomaMD presented results with MEDI2228, Anti BCMA ADC in refractory myeloma. It’s looking good with 60% response rate and duration of response of 6 months. Good to have a competitor to belantamab, especially if no keratopathy. #ASH20VR @MayoClinic

$VincentRK's tweet photo. #ASH20 My colleague @myelomaMD presented results with MEDI2228, Anti BCMA ADC in refractory myeloma. It’s looking good with 60% response rate and duration of response of 6 months. Good to have a competitor to belantamab, especially if no keratopathy. #ASH20VR @MayoClinic https://t.co/Vdw8o6eWFl$

Vincent Rajkumar

@VincentRK

almost 6 years ago

#ASH20 cilta-cel (BCMA directed CAR-T) previously known as LCAR-B38M, full name, ciltacabtagene autoleucel— outstanding results in refractory myeloma in CARTITUDE-1 trial. 67%CR, 34% MRD-, and >12 month PFS/response duration in CR patients of 85%. @DMadduri #ASH20VR

$VincentRK's tweet photo. #ASH20 cilta-cel (BCMA directed CAR-T) previously known as LCAR-B38M, full name, ciltacabtagene autoleucel— outstanding results in refractory myeloma in CARTITUDE-1 trial. 67%CR, 34% MRD-, and >12 month PFS/response duration in CR patients of 85%. @DMadduri #ASH20VR https://t.co/TYguVLnu72$

Vincent Rajkumar

@VincentRK

almost 6 years ago

#ASH20 ALLO-715 Allogeneic CAR-T for myeloma — long way to go. But interesting. Off the shelf approach. 60% responses at potential target dose. Don’t know why Sham dropped off twitter. Congrats Sham. #ASH20VR @DrMiguelPerales @sloan_kettering

VincentRK's tweet photo. #ASH20 ALLO-715 Allogeneic CAR-T for myeloma — long way to go. But interesting. Off the shelf approach. 60% responses at potential target dose. Don’t know why Sham dropped off twitter. Congrats Sham. #ASH20VR @DrMiguelPerales @sloan_kettering https://t.co/0Tzo0IVAg7

Vincent Rajkumar

@VincentRK

almost 6 years ago

#ASH20 ide-cel CAR-T results in refractory myeloma: 40% get CR— which is great. Of those, 30% have a response of >2 years— Also great. Problems: No plateau. Competition from BCMA bispecifics and ADCs. Competition from cilta-cel. Potential cost and complexity. #ASH20 #ASH20VR

$VincentRK's tweet photo. #ASH20 ide-cel CAR-T results in refractory myeloma: 40% get CR— which is great. Of those, 30% have a response of >2 years— Also great. Problems: No plateau. Competition from BCMA bispecifics and ADCs. Competition from cilta-cel. Potential cost and complexity. #ASH20 #ASH20VR https://t.co/uupKTMQ4l4$

Vincent Rajkumar

@VincentRK

almost 6 years ago

One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do it? The update of the IFM trial at #ASH20 addresses this question. https://t.co/jRz284llXL #ASH20VR Thread 👇

116

Vincent Rajkumar

@VincentRK

almost 6 years ago

Follow and search #ASH20VR for my commentaries (&critiques) on important myeloma related abstracts during #ASH20. I have used these personal hashtags selectively to avoid information overload. Check #ASH19VR for last years picks. @MyelomaTeacher @NorthTxMSG @grpetersen1

Vincent Rajkumar

@VincentRK

almost 6 years ago

#ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue font. Please add if I’m missing some. Exciting! #ASH20VR #mmsm @ASH_hematology @mtmdphd @SagarLonialMD @szusmani @NorthTxMSG

VincentRK's tweet photo. #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue font. Please add if I’m missing some. Exciting! #ASH20VR #mmsm @ASH_hematology @mtmdphd @SagarLonialMD @szusmani @NorthTxMSG https://t.co/oIrwZ9i0K3

128

Vincent Rajkumar

@VincentRK

almost 6 years ago

I have been using personal hashtags for a few years now. For key myeloma and healthcare cost related tweets check out: #MyelomaVR #CostVR For my picks at @ASH_hematology @ASCO etc check out: #ASH17VR #ASH18VR #ASH19VR #ASCO18VR #ASCO19VR #IMW2019VR #ASH19VR #ASH20VR

Vincent Rajkumar

@VincentRK

almost 6 years ago

#1 Talquetamab, novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) & CD3 shows activity in relapsed refractory myeloma. High response rates (78%) @ 20-180 mcg/kg dose levels. #ASH20 #ASH20VR @MountSinaiNYC @BerdejaJesus @JanssenUS https://t.co/JQLuIwZ4uE

Vincent Rajkumar

@VincentRK

almost 6 years ago

#2 Novel bi-specific antibody BFCR4350A which targets FcRH5 (universally expressed on plasma cells) and CD3 shows clinical activity in relapsed refractory myeloma. @CohenAd_MMdoc @Rfonsi1 @PennCancer @genentech #ASH20 #ASH20VR https://t.co/m0mjgWnwfr

$VincentRK's tweet photo. #2 Novel bi-specific antibody BFCR4350A which targets FcRH5 (universally expressed on plasma cells) and CD3 shows clinical activity in relapsed refractory myeloma. @CohenAd_MMdoc @Rfonsi1 @PennCancer @genentech #ASH20 #ASH20VR https://t.co/m0mjgWnwfr https://t.co/eZ1TvkEzGH$

Vincent Rajkumar

@VincentRK

almost 6 years ago

#3 Long term results of IFM 2009 trial shows similar overall survival after 8 years follow up between early vs delayed transplant in the modern era with VRd therapy. Particularly important info at time of COVID. #ASH20 #ASH20VR @PerrotAurore @Mohty_EBMT https://t.co/jRz284llXL

Vincent Rajkumar

@VincentRK

almost 6 years ago

#4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA locus at 16p. Important work. #ASH20 #ASH20VR @DanaFarber @NoopurRajeMD https://t.co/BkTMEaVXBu

Top Tweets for #ASH20VR

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users